Staar Surgical Co

STAANASDAQ · USD
26.39USD0.00 (-1.46%)
577

Staar Surgical Co (STAA) Covered Calls

Staar Surgical Co trades in the Medical Instruments & Supplies industry with an IV Rank of 29.76%, low versus the past year. STAA's highest covered call setup is the $30.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 12.02% out of the money with 8 days to expiration, a 12.21% return until expiration, and a 557.11% theoretical annualized return. Across the setups shown, annualized returns run from 64.07% to 557.11% at strikes between $27.50 and $40.00, with 8 to 217 days to expiration, as of Nov 12, 2026.

Read more

Running STAA covered calls helps you generate income from Staar Surgical Co shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best STAA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If STAA stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling STAA covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given STAA covered call is worth writing.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices.

2026-11-20830.0012.020.050.20327.0012.21557.11-0.19+0.113410.15
2026-12-183635.0030.690.100.30832.0031.07314.99-0.37+0.093020.20
2026-12-183632.5021.360.250.45597.0022.29226.02-0.93+0.163460.20
2026-11-20827.502.690.550.85127.004.74216.37-2.05+0.41810.30
2026-12-183630.0012.020.500.90372.0013.89140.84-1.87+0.283780.40
2027-03-1912737.5040.030.052.751077.0040.22115.58-0.19+0.26392.70
2027-03-1912735.0030.690.402.90862.0032.1992.51-1.49+0.3172.50
2027-06-1721740.0049.370.353.401357.0050.6785.23-1.31+0.2903.05
2026-12-183627.502.691.251.60197.007.3674.58-4.67+0.484170.35
2027-03-1912732.5021.360.253.50597.0022.2964.07-0.93+0.366023.25

As of Nov 12, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryMedical Instruments & Supplies
  • SectorHealthcare
  • IV Rank29.76% Low
  • Market cap (M$)1,325
  • 52 weeks high-26.43%
  • 52 weeks low69.38%
  • Analyst recommendationHold
    2.60
  • Target price$29.25
    10.84% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-04
  • P/E—
  • Future P/E45.12
  • EPS (ttm)0.00
  • EPS growth next 5 years—

As of Nov 13, 2026